A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and determine the
recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid
leukemia with and without T315I mutations in patients who are relapsed, refractory or
intolerant to TKIs.